Safety, Tolerability, and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B | Zendy

Jeffrey T. Guptill | Zendy; Shruti M. Raja | Zendy; Vern C. Juel | Zendy; Emmanuel B. Walter | Zendy; Michael CohenWolkowiez | Zendy; Heather Hill | Zendy; Eli A. Sendra | Zendy; B. Hauser | Zendy; Piper Jackson | Zendy; Geeta K. Swamy | Zendy

Open Access

Safety, Tolerability, and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B

Author(s) -

Jeffrey T. Guptill,

Shruti M. Raja,

Vern C. Juel,

Emmanuel B. Walter,

Michael CohenWolkowiez,

Heather Hill,

Eli A. Sendra,

B. Hauser,

Piper Jackson,

Geeta K. Swamy

Publication year - 2021

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02329-20

Subject(s) - pharmacokinetics , tolerability , monoclonal antibody , medicine , pharmacology , botulinum toxin , toxin , anesthesia , antibody , adverse effect , immunology , microbiology and biotechnology , biology

Botulism is a rare, life-threatening paralytic disease caused byClostridium botulinum neurotoxin (BoNT). Available treatments, including an equine antitoxin and human immune globulin, are given postexposure and challenging to produce and administer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research